Polycystic ovary syndrome is one of the most common endocrinopathies in women, can present with anovulation in adolescence, and is often accompanied by cardiometabolic disease. In many patients with PCOS, reproductive dysfunction is related to excess weight. Trials that induce weight loss through lifestyle interventions have demonstrated some effectiveness in improving reproductive measures. The effects reproductive and metabolic effects of glucagon-like peptide-1 receptor agonist therapy induced weight loss in patients with PCOS will be reviewed, in particular data from newer GLP1 RA and in the adolescent population.